Why Peptide Purity Thresholds Matter
Almost every research peptide sold in the United States is advertised at 98% or above. The number is so uniform across the market that it has stopped carrying information. Ninety-nine percent, 99%+, ≥98% — these appear on suppliers whose analytical practices could not be more different, which is a good sign that the figure is being used as a badge rather than a measurement.
The threshold is worth defending anyway. It just needs to be defended for the right reason, and the right reason is not the one usually given. This article covers where the number actually comes from, why the regulatory framework it is borrowed from explicitly declines to cover peptides, and what a threshold has to be paired with before it constrains anything.
Where 98% comes from — and the awkward fact underneath it
Ask a supplier to justify the number and the answer, if there is one, gestures at ICH — the International Council for Harmonisation guidelines that set impurity expectations for pharmaceutical substances. ICH Q3A(R2), Impurities in New Drug Substances, is the document in question. Its Attachment 1 sets, for a maximum daily intake of 2 g or less, a reporting threshold of 0.05%, an identification threshold of 0.10% (or 1.0 mg per day, whichever is lower) and a qualification threshold of 0.15% (or 1.0 mg per day, whichever is lower). Above 2 g per day the figures tighten to 0.03% / 0.05% / 0.05%.
Those numbers are real and they are strict. They are also, on the guideline’s own terms, not about peptides. Q3A(R2) states its scope directly: it does not cover “biological / biotechnological, peptide, oligonucleotide, radiopharmaceutical, fermentation product and semi-synthetic products derived therefrom, herbal products, and crude products of animal or plant origin.” The guideline applies to new drug substances produced by chemical synthesis, and it carves peptides out by name.
So the framework most often cited to justify a peptide purity threshold begins by saying it is not the framework for peptides. That is not a gotcha — the exclusion exists because peptide impurity profiles are dominated by species so structurally close to the parent that a small-molecule threshold model fits them badly. But it does mean that “98% meets ICH” is not a statement anyone can support, and a supplier who offers it has not read the document.
What US regulators do say about synthetic peptides
There is a purpose-built US framework, and it is narrower and more specific than the borrowed one.
The FDA guidance ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin addresses synthetic versions of five named peptides previously approved as recombinant products: glucagon, liraglutide, nesiritide, teriparatide and teduglutide. Within that scope the agency’s headline expectation is a specified peptide-related impurity level of no more than 0.5% of the drug substance, together with the requirement that any impurity shared with the reference product be present at an equal or lower level, and that any genuinely new specified impurity be justified.
Two things follow. First, the operative regulatory number for synthetic peptides in the US is expressed as a ceiling on an individual impurity, not as a floor on total purity. A lot at 99.4% total purity containing one unidentified 0.6% species is, under that logic, worse than a lot at 98.6% whose impurities are all below 0.2% and all characterized.
Second, none of it applies to research-grade material. These are requirements for abbreviated new drug applications. Research peptides are not made to that standard, are not reviewed against it, and are not sold as pharmaceutical products. A supplier quoting the framework at you should be able to say which parts they have actually adopted.
A threshold is a statement about a method
Here is the part that matters more than the number. A purity percentage is the output of a procedure, and three well-documented properties of that procedure decide what the percentage means.
Area percent is not mass percent. Reversed-phase purity is normally reported as main peak area divided by total integrated area on a UV chromatogram at 214 nm, where the peptide bond absorbs. But side chains absorb too, and unequally. Kuipers and Gruppen, in the Journal of Agricultural and Food Chemistry in 2007 (PMID 17539659), measured molar extinction coefficients at 214 nm for the constituent amino acids and found the peptide bond contributing roughly 923 M⁻¹cm⁻¹ while tryptophan contributes something near thirty times that, and phenylalanine, tyrosine and histidine around six times. An impurity that has lost an aromatic residue therefore under-reports relative to its mass, and one that has gained an oxidation is not detected by absorbance at all. Two lots at “98%” with different impurity compositions do not contain the same amount of the intended peptide.
A UV detector cannot see what does not absorb. Choules and colleagues, in the Journal of Pharmaceutical and Biomedical Analysis in 2020 (PMID 31671336), applied quantitative proton NMR to commercially sourced custom synthetic peptides and found undeclared mannitol at 20% and 43% by weight in two of them. Mannitol is UV-transparent and poorly retained on reversed phase, so it is invisible to the method that produced the purity certificate. Both materials could carry a high purity figure while being, by mass, largely something else. This is the single cleanest demonstration that a purity percentage is a statement about a chromatogram, not about the contents of a vial.
The counterion and the water are real mass, and not always inert. Synthetic peptides are typically isolated as trifluoroacetate salts, and residual TFA plus adsorbed water can account for a substantial fraction of a lyophilized vial’s weight. It is not merely ballast. Cornish and colleagues, in the American Journal of Physiology in 1999 (PMID 10567002), reported that trifluoroacetate present as a contaminant in purified proteins inhibited proliferation of osteoblasts and chondrocytes at concentrations that arrive with ordinary peptide preparations — a bioactive artifact that has been mistaken for the activity of the peptide under study.
What is actually in the two percent
The residual fraction is usually discussed as if it were an undifferentiated smear. It is not.
Huo and colleagues, in Analytical and Bioanalytical Chemistry in 2022 (414:6485-6495), took a single 14-residue synthetic antimicrobial peptide, Cbf-14, and characterized 33 structurally related impurities by HPLC-QTOF-MS/MS: one process-related and thirty-two degradation products, comprising fifteen hydrolysis derivatives, five structural isomers, four acetylated variants, two aldimine compounds and six oxidized forms. Seven were independently synthesized to confirm the assignments. The authors note the species had not previously been declared in commercially sourced synthetic material.
Thirty-three distinguishable impurities. In one short peptide. That is the population that a single percentage compresses into one digit — and it is why the FDA framing, a ceiling on each specified impurity, is the more informative construction. A deletion analog at 0.8% and a residual solvent at 0.8% are the same number and very different experimental risks.
The honest version of our own numbers
Our TB-500 lot is not 99%. It is 98.62%, and the certificate says so.
Report DBAV-TB500-10-051226, tested 23 May 2026 by Testides Analytical, records expected content 10.00 mg, measured content mass 9.84 mg, purity 98.62% by HPLC-UV at 214 nm, fill accuracy 98.4%, appearance white lyophilized powder. It is linked from our TB-500 10MG batch certificate and the report number is printed so it can be matched against the vial.
We are drawing attention to it deliberately, because the comparison a laboratory should be making is not 98.62% against a competitor’s 99%+. It is 98.62% with a report number, a test date, a named laboratory, a measured content mass and a stated method against a round number with none of those. The first is checkable. The second is a claim about a claim.
Two limitations of that document belong in the same paragraph rather than in a footnote. It is an HPLC-UV analysis, so everything said above about UV-transparent constituents applies to it as much as to anyone’s. And it carries no mass spectrometry section, so identity rests on the synthesis and supply record rather than on an independent spectral measurement. Stating that is not a weakness in the certificate. It is the difference between a control record and a sales asset.
What to require before a threshold means anything
- The method, named. Column chemistry, gradient, detection wavelength. A percentage without a method is a number without units.
- Content mass alongside purity. Purity cannot distinguish a full vial of good material from a light vial of good material. Both figures, or neither is useful.
- The individual impurity ceiling, not just the total. Ask what the largest single non-main peak was. That one number tells you more than the headline.
- Net peptide content, if the work is quantitative. Total mass includes counterion and water. For anything concentration-dependent, the peptide fraction is the number that belongs in the calculation.
- Lot-specific, traceable documentation. A certificate for a compound is not a certificate for a shipment. The report number should appear on both the PDF and the label.
The US supply context
The domestic landscape consolidated through 2025 and 2026, and a large number of US laboratories re-sourced material against certificates issued under undisclosed and non-equivalent methods. In that situation the round numbers converge and stop discriminating, while the documentation practices diverge sharply — which is where the real signal is.
Maple Research Labs is a Wyoming entity shipping same day from Santa Barbara, California, with a batch-specific certificate linked from every product page. Domestic stock shortens ambient transit, and that has an analytical consequence rather than only a convenience one: hydrolysis, oxidation and deamidation are functions of time and temperature, and three of the five degradation classes Huo and colleagues catalogued are exactly those processes. A certificate describes material as it was when tested. The shorter the interval between that test and the bench, the closer the document is to the truth.
The short version
Ninety-eight percent is a reasonable expectation and a poor differentiator. The ICH thresholds usually invoked to justify it exclude peptides in their own scope statement; the US framework that does address synthetic peptides sets a ceiling on individual impurities rather than a floor on total purity. A purity figure is the output of a UV method that cannot see non-absorbing material, weights aromatic residues thirty-fold, and says nothing about counterion, water or vial content. Demand the method, the content mass, the largest single impurity and a lot-traceable report number — and treat an unsupported round number as the least informative thing on the page.
References
- International Council for Harmonisation. Q3A(R2): Impurities in New Drug Substances — Attachment 1 thresholds and scope exclusions.
- US Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin — Guidance for Industry.
- Kuipers BJH, Gruppen H. Prediction of molar extinction coefficients of proteins and peptides from constituent amino acid UV absorption at 214 nm, enabling quantitative RP-HPLC-MS analysis. J Agric Food Chem. 2007;55(14):5445-5451. PMID 17539659.
- Choules MP, Klein LL, Lankin DC, et al. NMR reveals an undeclared constituent in custom synthetic peptides. J Pharm Biomed Anal. 2020;178:112982. PMID 31671336.
- Cornish J, Callon KE, Lin CQ, et al. Trifluoroacetate, a contaminant in purified proteins, inhibits proliferation of osteoblasts and chondrocytes. Am J Physiol. 1999;277(5):E779-E783. PMID 10567002.
- Huo Y, Xu K, Lu Y, Ma L, Zhou C, Hang T, Song M. Characterization of structurally related peptide impurities by HPLC-QTOF-MS/MS, applied to the antimicrobial peptide Cbf-14. Anal Bioanal Chem. 2022;414:6485-6495.
- D’Hondt M, Gevaert B, Wynendaele E, De Spiegeleer B. Implementation of a single quad MS detector in routine quality control analysis of peptide drug substances. J Pharm Anal. 2016;6(1):24-31. PMID 29403959.
- United States Pharmacopeia, General Chapter <621> Chromatography and <1225> Validation of Compendial Procedures; ICH Q2(R2) and Q6A.
Batch data cited from Certificate of Analysis DBAV-TB500-10-051226 (Testides Analytical, tested 23 May 2026), linked from the TB-500 10MG product listing.
All compounds supplied by Maple Research Labs are for research use only. They are not for human use or consumption, are not drugs, foods or cosmetics, and are not intended to diagnose or affect any condition in people or animals. All work described here refers to in vitro systems, analytical reference materials, and published preclinical and analytical studies.